EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma

Gael S Roth, Jérôme Cros, Cindy Neuzillet, Emilie Barbier, Meriem Guarssifi, Amel Bennacer, Michel Ducreux, Marie Muller, Julien Edeline, Sylvain Manfredi, Nicolas Williet, Nelson Dusetti und 6 weitere

Digestive and Liver Disease · 2026

DOI: 10.1016/j.dld.2026.01.211 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Digestive and Liver Disease, 2026. Verfasst von Gael S Roth und 17 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Grenoble Alpes - Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes - Equipe BIOMICS - Laboratoire Biosciences et Bi…. Hauptthemen laut MEDLINE: Deoxycytidine, Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Capecitabine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ampullary adenocarcinoma (AAC) is a rare and aggressive cancer with a 5-year overall survival (OS) rate ranging from 30% to 67% after resection due to a high recurrence rate. Yet, adjuvant therapy's role is still debated. Recent French FFCD-AC cohort study highlighted that adjuvant therapy, can benefit intermediate and high-risk patients. Chemotherapy regimens, include gemcitabine and 5-fluorouracil (5FU) but practices are highly heterogenous due to the low level of evidence. Previous studies suggest that combination chemotherapy, such as mFOLFIRINOX, could offer improved outcomes. DESIGN: PRODIGE 98 - AMPIRINOX trial (NCT06813976) is a multicenter, open-label, randomized phase 3 trial designed to compare the efficacy of adjuvant mFOLFIRINOX versus single-agent chemotherapy (capecitabine or gemcitabine) in patients with resected AAC. Primary outcome is disease free survival and secondary outcomes include overall survival (OS), safety and quality of life. Patients (ages 18-79) must have undergone macroscopically complete (R0/R1) resection of AAC, with exclusion of patients previously treated with chemotherapy, and pT1N0M0 tumors. Ancillary studies will focus on an in-depth molecular profiling of AAC to identify prognostic and predictive biomarkers. AMPIRINOX is currently recruiting and is expected to provide essential data on how to optimize treatment for AAC patients in the coming years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsCapecitabineAmpulla of VaterCommon Bile Duct NeoplasmsHumansGemcitabineChemotherapy, AdjuvantFluorouracilLeucovorinOxaliplatinIrinotecanAgedAntimetabolites, AntineoplasticMiddle AgedDisease-Free SurvivalAdultQuality of LifeMaleFemale

Stichwörter der Autor:innen

Adjuvant chemotherapyAmpullary carcinomaCapecitabineGemcitabinemFOLFIRINOX

Substanzen

GemcitabineDeoxycytidineCapecitabineFluorouracilLeucovorinOxaliplatinIrinotecanfolfirinoxAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Univ. Grenoble Alpes - Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes - Equipe BIOMICS - Laboratoire Biosciences et Bioingénierie pour la santé (BGE) UA13 INSERM/CEA Grenoble/Université Gr…
  • Université Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, Paris F-75018, France; Université Paris Cité, Service d'Anatomopathologie, Centre Hospitalier Universitaire Beaujon/Bic…
  • GI Oncology, Department of Medical Oncology, Institute Curie - Site Saint Cloud, Versailles Saint-Quentin University, Paris Saclay University, Saint-Cloud, Molecular Oncology, UMR144, Institute Curie, Paris, France.
  • Fédération Francophone de Cancérologie Digestive (FFCD), EPICAD INSERM LNC-UMR 1231, Faculté de Médecine, Université Bourgogne Europe, 7, Boulevard Jeanne d'Arc, 21079 Dijon, France.
  • Department of Medicine, Gustave Roussy Hospital, INSERM U1279, Villejuif, University of Paris Saclay, Orsay, France.
  • Department of Hepato-Gastroenterology and Digestive Oncology, University Hospital of Nancy (CHRU Nancy), University of Lorraine, Vandœuvre-lès-Nancy, France.

Zitieren

APA

Roth, G. S., Cros, J., Neuzillet, C., Barbier, E., Guarssifi, M., Bennacer, A., Ducreux, M., Muller, M., Edeline, J., Manfredi, S., Williet, N., Dusetti, N., Laurent-Puig, P., Ruffino, V., Chanez, B., Nicolle, R., Taieb, J., & Malka, D. (2026). Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2026.01.211

Vancouver

Roth GS, Cros J, Neuzillet C, Barbier E, Guarssifi M, Bennacer A, et al. Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma. Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2026.01.211

BibTeX
@article{Roth2026,
  author = {Roth, Gael S and Cros, Jérôme and Neuzillet, Cindy and Barbier, Emilie and Guarssifi, Meriem and Bennacer, Amel and Ducreux, Michel and Muller, Marie and Edeline, Julien and Manfredi, Sylvain and Williet, Nicolas and Dusetti, Nelson and Laurent-Puig, Pierre and Ruffino, Victoire and Chanez, Brice and Nicolle, Rémy and Taieb, Julien and Malka, David},
  title = {Randomized, multicenter Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or gemcitabine in patients with resected ampullary adenocarcinoma},
  journal = {Digestive and Liver Disease},
  year = {2026},
  doi = {10.1016/j.dld.2026.01.211}
}
Kostenlos starten →